Patents Issued in November 27, 2014
-
Publication number: 20140348778Abstract: Methods are disclosed herein for increasing survival of transplanted cells, either in vitro or in vivo. In additional embodiments, methods are disclosed for treating a subject with a spinal cord injury or a neurodegenerative disorder. The methods include administering to a subject a therapeutically effective amount of cells, such as bone marrow stromal cells, and a therapeutically effective amount of a reverse thermal gel composition. The reverse thermal gel compositing includes a triblock copolymer, or pharmaceutically acceptable salt thereof, having the structure B-A-B in which A is one of a polyurethane or poly(ester urethane) group that comprises one or more pendant active groups, blocked active groups or active agents and B is a hydrophilic block, wherein the composition is a gel at 25° C.-40° C. and a liquid solution at a lower temperature.Type: ApplicationFiled: August 13, 2014Publication date: November 27, 2014Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Yadong Wang, Martin Oudega
-
Publication number: 20140348779Abstract: A topical ophthalmic composition for treatment of dry eye is disclosed. In preferred embodiments, the composition comprises as active ingredients hyaluronic acid or a pharmaceutically acceptable salt thereof and polyvinylpyrrolidine. In other embodiments of the invention, the composition additionally comprises polyvinyl alcohol. Methods of preparation of the composition are disclosed, as well as methods for use of the composition in the treatment of dry eye.Type: ApplicationFiled: January 7, 2013Publication date: November 27, 2014Inventors: Eyal Zolotariov, Zvi Zolotariov
-
Publication number: 20140348780Abstract: Compositions and methods for treating infectious diseases produced by biofilms are disclosed. More specifically, the present disclosure refers to a pharmaceutical compositions which may be used for treating biofilm infections, specifically, biofilms formed by bacteria such as Pseudomonas, E. coli, Klebsiella, and other human pathogens. Pharmaceutical compositions may include a nutrient dispersion that can include sodium citrate, succinic acid, xylitol, glutamic acid, and ethylenediaminetetraacetic acid (EDTA), among others. Additionally disclosed pharmaceutical composition may include API such as antibiotics. Subsequently, the antibiotics agent may be ciprofloxacin, amikacin, tobramycin, colistin methate, or polymixin, among others. Pharmaceutical compositions disclosed may employ chemotactic agents in order to disrupt biofilms and therefore enhance the antibiotic response. Pharmaceutical compositions disclosed may include suitable vehicles which may depend on the dosage form.Type: ApplicationFiled: May 22, 2013Publication date: November 27, 2014Applicant: PROFESSIONAL COMPOUNDING CENTERS OF AMERICAInventor: Andrew B. Glasnapp
-
Publication number: 20140348781Abstract: In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-9 and uses related thereto, e.g., enhancing the adaptive immune system. Typically the GM-CSF and IL-9 are connected by a polymer linker, e.g., polypeptide. In certain embodiments, the disclosure relates to nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such a nucleic acids.Type: ApplicationFiled: May 20, 2014Publication date: November 27, 2014Applicants: CHILDREN'S HEALTHCARE OF ATLANTA, INC, EMORY UNIVERSITYInventors: Jacques Galipeau, Pingxin Li
-
Publication number: 20140348782Abstract: A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive T-cells and exposing the naive T-cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T-cells to gain immunization of the T-cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions.Type: ApplicationFiled: June 4, 2014Publication date: November 27, 2014Applicant: IRX Therapeutics, Inc.Inventor: John W. Hadden
-
Publication number: 20140348783Abstract: A method for overcoming mild to moderate immune suppression includes the steps of inducing production of naive T-cells and restoring T-cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naive T-cells and exposing the naive T-cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T-cells to gain immunization of the T-cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions.Type: ApplicationFiled: June 4, 2014Publication date: November 27, 2014Inventor: John W. Hadden
-
Publication number: 20140348784Abstract: Treatment of lesions of pathological angiogenesis, especially tumors, rheumatoid arthritis, diabetic retinopathy, age-related muscular degeneration, and angiomas. A conjugate is used comprising a molecule that exerts a biocidal or cytotoxic effect on target cells in the lesions and an antibody directed against an extracellular matrix component which is present in such lesions. The antibody may be directed against fibronectin-2 (IL-2), doxorubicin, interleukin-12 (IL-12), Interferon-? (IFN-?), Tumor Necrosis Factor ? (TNF?) or Tissue Factor protein (which may be truncated).Type: ApplicationFiled: June 5, 2014Publication date: November 27, 2014Applicant: PHILOGEN S.P.A.Inventors: Luciano ZARDI, Dario NERI, Barbara CARNEMOLLA, Fredrik NILSSON, Lorenzo TARLI, Laura BORSI, Cornelia HALIN
-
Publication number: 20140348785Abstract: Monoclonal neutralizing antibodies are disclosed that specifically bind to the HIV-1 gp41 membrane-proximal external region (MPER). Also disclosed are compositions including the disclosed antibodies that specifically bind gp41, nucleic acids encoding these antibodies, expression vectors including the nucleic acids, and isolated host cells that express the nucleic acids. The antibodies and compositions disclosed herein can be used for detecting the presence of HIV-1 in a biological sample, or detecting an HIV-1 infection or diagnosing AIDS in a subject. In additional, the broad neutralization breadth of the disclosed antibodies makes them ideal for treating a subject with an HIV infection. Thus, disclosed are methods of treating and/or preventing HIV infection.Type: ApplicationFiled: November 7, 2012Publication date: November 27, 2014Inventors: Mark Connors, Jinghe Huang, Leo B. Laub, Peter Kwong, Gary Nabel, John R. Mascola, Baoshan Zhang, Rebecca S. Rudicell, Ivelin Georgiev, Yongping Yang, Jiang Zhu, Gilad Ofek
-
Publication number: 20140348786Abstract: ?-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of ?-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising ?-mannosylceramide, as well as methods of treatment of tumors are also provided.Type: ApplicationFiled: August 7, 2014Publication date: November 27, 2014Inventors: Jay A. Berzofsky, Jessica J. O'Konek, Masaki Terabe, Petr A. Illarionov, Gurdyal S. Besra
-
Publication number: 20140348787Abstract: Compositions and methods for treating ear infections are disclosed. More specifically, these methods may refer to treatment of internal otitis using an otic composition, such as otic gel for animals and humans. Poloxamer otic gel may be in liquid state at room temperature and may change to gel at about temperature (64° F.) as poloxamer otic gel reaches body temperature, because of the thermo-reversible properties. Consequently, poloxamer otic gel may be an effective treatment in animals and humans, where poloxamer otic gel may reach otitis affected site and remain there for a longer period of time. Additionally, poloxamer otic gel may include APIs such as antifungals, antibiotics and corticosteroids, among others. Furthermore, poloxamer otic gel may be instilled inside the ear, employing calibrated delivery device into the vertical ear canal in order to reach the horizontal ear canal, without puncturing the tympanic membrane.Type: ApplicationFiled: May 22, 2013Publication date: November 27, 2014Applicant: PROFESSIONAL COMPOUNDING CENTERS OF AMERICAInventor: Chris V. Simmons
-
Publication number: 20140348788Abstract: The invention describes a method to modulate melanosome maturation process in melanocytes. Further, it describes a method to reversibly alter the process of pigmentation in the human epidermal skin. The method targets melanosome maturation and its transfer to keratinocytes, which are key processes involved in the pigmentation for its potential use in predictable and controlled regulation of pigmentation in human skin.Type: ApplicationFiled: May 16, 2012Publication date: November 27, 2014Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCHInventors: Rajesh Sudhir Gokhale, Vivek Tirunelveli Natarajan, Parul Ganju
-
Publication number: 20140348789Abstract: This disclosure relates to a modified ?-helical bundle cytokine, with reduced activity via an ?-helical bundle cytokine receptor, wherein the ?-helical bundle cytokine is specifically delivered to target cells. Preferably, the ?-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified ?-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified ?-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.Type: ApplicationFiled: January 17, 2013Publication date: November 27, 2014Inventors: Jan Tavernier, Gilles Uzé, Guillaume Cartron, Franciane Paul, Jacob Piehler
-
Publication number: 20140348790Abstract: The nucleic acid sequences of adeno-associated virus (AAV) serotype 1 are provided, as are vectors and host cells containing these sequences and functional fragments thereof. Also provided are methods of delivering genes via AAV-1 derived vectors.Type: ApplicationFiled: December 20, 2013Publication date: November 27, 2014Applicant: The Trustees of the University of PennsylvaniaInventors: James M. Wilson, Weidong Xiao
-
Publication number: 20140348791Abstract: The present invention relates to recombinant adenovirus serotype 5 (Ad5) vectors which harbor chimeric capsid proteins including substitutions of the corresponding regions from adenovirus serotypes having a lower seroprevalence relative to Ad5. In particular, the chimeric capsid includes modifications of both the adenoviral hexon and fiber proteins. The invention also provides methods for the treatment of diseases or disorders caused by infective agent(s) by administering the adenoviral vector(s) to a subject (e.g., a mammal, such as a human).Type: ApplicationFiled: September 7, 2012Publication date: November 27, 2014Applicant: Beth Israel Deaconess Medical Center, Inc.Inventors: Dan H. Barouch, Ritu Bradley
-
Publication number: 20140348792Abstract: Methods for reducing or inhibiting polyposis or colorectal cancer are provided. The methods comprise administering to a mammal a bacterium modified to decrease the display of lipoteichoic acid on the cell surface. Administration of the recombinant bacterium promotes a desired therapeutic response. The recombinant bacterium may be administered in a single dose or series of doses. Methods find use in treating or preventing a variety of polyp-related disorders, for example, treating or Lynch syndrome, familial adenomatous polyposis, and colorectal cancer.Type: ApplicationFiled: December 18, 2012Publication date: November 27, 2014Inventors: Todd Klaenhammer, Mansour Mohamadzadeh
-
Publication number: 20140348793Abstract: The present invention relates generally to a method of regenerating the hippocampus in a mammal and agents for use therein. More particularly, the present invention provides a method of regenerating the hippocampus in a mammal by administering a sub-population of neural crest stem cells. The method of the present invention is useful in the treatment of conditions characterised by a defective hippocampus, such as neuropsychiatric disorders.Type: ApplicationFiled: December 13, 2012Publication date: November 27, 2014Inventors: Angel Lopez, Quenten Schwarz
-
Publication number: 20140348794Abstract: The present invention provides an adeno-associated virus 4 (AAV4) virus and vectors and particles derived therefrom. In addition, the present invention provides methods of delivering a nucleic acid to a cell using the AAV4 vectors and particles.Type: ApplicationFiled: August 14, 2014Publication date: November 27, 2014Inventors: John A. Chiorini, Robert M. Kotin, Brian Safer
-
Publication number: 20140348795Abstract: A nutraceutical compound designed to promote cellular health, cleanse and replenish a body's gastro-intestinal tract and system, balance a body's natural defense system, keep the immune system high, and keep intestinal bacteria feeding on the correct enzymes is disclosed. More specifically, a nutraceutical compound that includes glutathione, carnosin, B vitamins, amino acids, probiotics, aloe vera, chlorella, spirulina, fruit powders, superfoods, and minerals is disclosed.Type: ApplicationFiled: May 27, 2014Publication date: November 27, 2014Inventors: Helmut Wyzisk, Michael J. Sloggett
-
Publication number: 20140348796Abstract: This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions.Type: ApplicationFiled: August 8, 2014Publication date: November 27, 2014Inventors: Rémy Burcelin, Didier Carcano, Sampo Lahtinen
-
Publication number: 20140348797Abstract: To provide a method for inhibiting the proliferation of a plant pathogenic bacterium. A method for inhibiting the proliferation of a plant pathogenic bacterium, including culturing a microorganism having an ability to inhibit the proliferation of a plant pathogenic bacterium and belonging to the genus Collimonas, and seeding the cultured microorganism to a plant soil.Type: ApplicationFiled: December 16, 2011Publication date: November 27, 2014Applicants: New Environmental Technology Council, Kinki UniversityInventors: Takashi Ano, Yoichiro Hirose
-
Publication number: 20140348798Abstract: The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.Type: ApplicationFiled: March 7, 2014Publication date: November 27, 2014Applicant: NOVARTIS AGInventors: Paul L. HALLENBECK, Seshidhar Reddy POLICE, Laura M. HALES, Carl M. HAY, Shanthi GANESH, Ling XU, Jingping YANG, Cheng CHENG
-
Publication number: 20140348799Abstract: The present invention relates to a novel bacteriophage having a specific bactericidal activity against salmonella, a composition for the prevention or treatment of infectious diseases comprising the bacteriophage as an active ingredient, an antibiotic comprising the bacteriophage as an active ingredient, an animal feed or drinking water comprising the bacteriophage as an active ingredient, and a sanitizer or cleaner comprising the bacteriophage as an active ingredient. The novel bacteriophage of the present invention has a specific bactericidal activity against Salmonella choleraesuis, Salmonella typhimurium, Salmonella derby, Salmonella infantis or Salmonella newport with no influences on beneficial bacteria, as well as excellent acid- and heat-resistance and desiccation tolerance.Type: ApplicationFiled: September 20, 2012Publication date: November 27, 2014Inventors: Si Yong Yang, Jae Won Kim, Young Wook Cho, Young Sa Kim, Eun Mi Shin
-
Publication number: 20140348800Abstract: A bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture. A treatment agent, such as a cell type or a growth factor, can be added to either the first mixture or the second mixture. In some embodiments, the treatment agent is not added to either mixture. The first mixture can be co-injected with the second mixture to form a bioscaffolding in an infarct region for treatment thereof.Type: ApplicationFiled: May 29, 2014Publication date: November 27, 2014Applicant: Abbott Cardiovascular Systems Inc.Inventors: Gene Michal, Shubhayu Basu
-
Publication number: 20140348801Abstract: Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated for augmentation or regeneration of vocal cords. The suspension of autologous fibroblasts, grown from a biopsy of each individual's own buccal mucosa or skin using current good manufacturing practices (CGMP) and standard tissue culture procedures, is supplied in vials containing cryopreserved fibroblasts or precursors thereof, having a purity of at least 98% fibroblasts and a viability of at least 85%, for administration of from one to six mL, preferably two mL administered three tunes approximately three to six weeks apart, of cells at a concentration of from 1.0-2.0×107 cells/mL.Type: ApplicationFiled: June 3, 2014Publication date: November 27, 2014Applicant: Fibrocell Technologies, Inc.Inventor: John Maslowski
-
Publication number: 20140348802Abstract: The invention provides compositions comprising stem and/or progenitor cells that have been treated to enhance the therapeutic properties of the cells for treating ischemia. In particular, the present invention relates to the use of stem and/or progenitor cells having enhanced therapeutic properties to treat an ischemic tissue, a tissue damaged by ischemia, or at least one symptom associated with an ischemic tissue or a tissue damaged by ischemia.Type: ApplicationFiled: November 29, 2012Publication date: November 27, 2014Inventors: Dan Shoemaker, Pratik S. Multani, John D. Mendlein, David Robbins
-
Publication number: 20140348803Abstract: This document relates to compositions containing cardiogenic factors, to methods to obtain cells by culturing initial cells in the presence of such factors; and methods of administering the obtained cells to heart tissue.Type: ApplicationFiled: August 6, 2014Publication date: November 27, 2014Inventors: Andre Terzic, Atta Behfar
-
Publication number: 20140348804Abstract: The present invention relates to a proteinaceous extract derived from tortoise spleen and to a tetrapeptide FTGN, which have stimulatory activity on hematopoietic cells. In particular, this tetrapeptide enhances hemopoietic reconstruction, and bone marrow re-population, reduced as a consequence of a high dose of radiation or chemotherapy exposure. The invention further provides pharmaceutical compositions comprising as an effective ingredient the proteinaceous extract or the FTGN tetrapeptide and ex vivo and in vivo methods of treatment employing them.Type: ApplicationFiled: August 11, 2014Publication date: November 27, 2014Inventor: Azim TURDIEV
-
Publication number: 20140348805Abstract: The present invention is directed to a high affinity T cell receptor (TCR) against a tumor-associated antigen, an isolated nucleic acid molecule encoding same, a T cell expressing said TCR, and a pharmaceutical composition for use in the treatment of diseases involving malignant cells expressing said tumor-associated antigen.Type: ApplicationFiled: March 25, 2014Publication date: November 27, 2014Applicant: Max-Delbrueck-Centrum fur Molekulare Medizin Berlin-BuchInventors: Dolores Jean Schendel, Susanne Wilde, Bernhard Frankenberger, Wolfgang Uckert
-
Publication number: 20140348806Abstract: Cell based therapy comprises administration to the lung by injection into the blood system of viable, mammalian cells effective for alleviating or inhibiting pulmonary disorders. The cells may express a therapeutic transgene or the cells may be therapeutic in their own right by inducing regenerative effects.Type: ApplicationFiled: June 13, 2014Publication date: November 27, 2014Applicant: Northern Therapeutics, Inc.Inventor: Duncan John Stewart
-
Publication number: 20140348807Abstract: The present invention concerns methods for administering to a subject plantaricins A, N or K and/or a biomass having at least one plantaricin selected from plantaricins A.Type: ApplicationFiled: May 13, 2014Publication date: November 27, 2014Applicant: GIULIANI S.p.A.Inventors: Giammaria GIULIANI, Anna Benedusi, Marco Gobbetti, Raffaella Di Cagno, Maria De Angelis, Maria Calasso
-
Publication number: 20140348808Abstract: The present invention relates to immunomodulatory cells, methods for providing immunomodulatory cells, and therapeutic uses of the cells for the immune modulation of mammals in need thereof.Type: ApplicationFiled: May 18, 2012Publication date: November 27, 2014Inventor: Olga De La Rosa
-
Publication number: 20140348809Abstract: Compositions and methods are provided for generating T cells having a regulatory phenotype from conventional T (Tconv) cells. Such compositions and methods include culturing isolated, naïve Tconv cells with an effective amount of interleukin-35 (IL-35) until the cells have the regulatory phenotype. Also provided are methods to treat subject having or susceptible to having various disorders including, for example, immune system disorders with the T cells having the regulatory phenotype.Type: ApplicationFiled: August 8, 2014Publication date: November 27, 2014Inventors: Dario AA. Vignali, Lauren W. Collison
-
Publication number: 20140348810Abstract: An in situ gel-forming composition is disclosed. The in situ gel-forming composition comprises one or more absorbable polymers, solvents such as N-methyl-2-pyrrolidone, polyethylene glycol or DMSO, and optionally one or more bioactive agent. The composition forms a hydrogel or semi-solid mass on contact with an aqueous environment. The method of using in situ gel-forming composition for various applications is also disclosed.Type: ApplicationFiled: August 8, 2014Publication date: November 27, 2014Applicant: POLY-MED, INC.Inventor: Shalaby W. Shalaby
-
Publication number: 20140348811Abstract: The present invention provides compositions comprising sugar, cysteine, and/or sugar-cysteine products, methods of preparing the same, and/or using the same.Type: ApplicationFiled: July 27, 2012Publication date: November 27, 2014Applicant: MAX INTERNATIONAL, LLCInventors: Herbert T. Nagasawa, David Bagley, Scott Momii, Scott Nagasawa
-
Publication number: 20140348812Abstract: The present invention relates generally to the field of obesity and complications arising therefrom and in particular to the control of obesity by inhibiting adipogenesis and related processes.Type: ApplicationFiled: August 6, 2014Publication date: November 27, 2014Inventors: Antonio RAJIC, Dominic J. AUTELITANO, Ana K. VRKIC, Christopher G. HOSKING, Leodevico L. ILAG
-
Publication number: 20140348813Abstract: Provided are compositions comprising a cocaine esterase (CocE) and a compound that thermostabilizes the CocE. Also provided are methods of thermostabilizing a cocaine esterase. Additionally provided are methods of treating a mammal undergoing a cocaine-induced condition. Methods of determining whether a compound is a thermostabilizing agent for a protein are also provided. Uses of the above-described compositions for the treatment of a cocaine-induced condition is additionally provided. Additionally provided is an isolated nucleic acid encoding a CocE polypeptide having the substitutions L169K and G173Q, and the CocE polypeptide encoded by that nucleic acid, and pharmaceutical compositions thereof. Further provided is the use of that composition for the manufacture of a medicament for the treatment of a cocaine-induced condition and for the treatment of a cocaine-induced condition.Type: ApplicationFiled: January 28, 2014Publication date: November 27, 2014Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, The Trustees of Columbia University in the City of New YorkInventors: Donald W. Landry, James H. Woods, Roger K. Sunahara, Diwahar L. Narasimhan, Joanne MacDonald, Milan N. Stojanovich, John J. Tesmer, Remy L. Brim
-
Publication number: 20140348814Abstract: The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.Type: ApplicationFiled: March 14, 2014Publication date: November 27, 2014Applicant: Polaris GroupInventors: Robert Almassy, Richard E. Showalter, James A. Thomson, Wes Sisson, Wei-Jong Shia, Li-Chang Chen, Yang Lee
-
Publication number: 20140348815Abstract: Microencapsulation of bioactive and chemical cargo in a stable, cross-linked polymer matrix is presented that results in small particle sizes and is easily scaled-up for industrial applications. A formulation of a salt of an acid soluble multivalent ion, an acid neutralized with a volatile base and one or more monomers that cross-link in the presence of multivalent ions is atomized into droplets. Cross-linking is achieved upon atomization where the volatile base is vaporized resulting in a reduction of the pH of the formulation and the temporal release of multivalent ions from the salt that cross-link the monomers forming a capsule. The incorporation of additional polymers or hydrophobic compounds in the formulation allows control of hydration properties of the particles to control the release of the encapsulated compounds. The operational parameters can also be controlled to affect capsule properties such as particle-size and particle-size distribution.Type: ApplicationFiled: May 27, 2014Publication date: November 27, 2014Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Tina Jeoh-Zicari, Herbert B. Scher, Monica C. Santa-Maria, Scott Strobel
-
Publication number: 20140348816Abstract: The invention also relates to the use of these complex forms for the purposes of screening for biological or chemical compounds capable of modulating a biological activity of said complex forms and/or for preparing and/or improving a pluristratified cell model.Type: ApplicationFiled: July 10, 2014Publication date: November 27, 2014Applicant: L'OREALInventors: Mark DONOVAN, Dominique Bernard
-
Publication number: 20140348817Abstract: Methods and diagnostic agents for identification of subjects for cancer treatment with an anti-hyaluronan agent, such as a hyaluronan-degrading enzyme, are provided. Diagnostic agents for the detection and quantification of hyaluronan in a biological sample and monitoring cancer treatment with an anti-hyaluronan agent, for example a hyaluronan-degrading enzyme, are provided. Combinations and kits for use in practicing the methods also are provided.Type: ApplicationFiled: August 14, 2014Publication date: November 27, 2014Inventors: Ping Jiang, H. Michael Shepard, Lei Huang
-
Publication number: 20140348818Abstract: Biomarkers of Kawasaki Disease (KD) are provided. In certain aspects, methods are provided for detecting KD biomarkers, such as elevated PDGFC expression. Likewise, methods of treating a subject having a biomarker of KD are described.Type: ApplicationFiled: December 21, 2012Publication date: November 27, 2014Inventors: Virginia M. Pascual, Zhaohui Xu, Octavio Ramilo, Rolando Cimaz
-
Publication number: 20140348819Abstract: The present invention provides methods of treating cancer.Type: ApplicationFiled: June 22, 2012Publication date: November 27, 2014Applicants: Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc.Inventors: Todd Golub, Ravid Straussman
-
Publication number: 20140348820Abstract: The present disclosure relates to immunoglobulins with reduced aggregation and compositions, methods of generating such immunoglobulins with computational tools and methods of using such immunoglobulins particularly in the treatment and prevention of disease.Type: ApplicationFiled: April 29, 2014Publication date: November 27, 2014Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, NOVARTIS AGInventors: Naresh CHENNAMSETTY, Bernhard HELK, Veysel KAYSER, Bernhardt TROUT, Vladimir VOYNOV
-
Publication number: 20140348821Abstract: Methods of testing to identify and to treat a subset of colon cancer patients exhibiting dMMR tumor tissue, who derive significant clinical benefit from the addition of bevacizumab to standard adjuvant chemotherapy. The presence of a V600E BRAF mutation is also of significance.Type: ApplicationFiled: May 23, 2014Publication date: November 27, 2014Applicant: NSABP Foundation, Inc.Inventors: Katherine Lea Pogue-Geile, Soonmyung Paik
-
Publication number: 20140348822Abstract: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2). In certain embodiments, the invention provides methods of treating diseases such as Alzheimer's Disease, Parkinson's Disease or amyotrophic lateral sclerosis using amyotrophic disease-specific epitopes, and compositions including these epitopes. The invention also provides antibodies that bind to monomeric or misfolded SOD1, and not on the molecular surface of native homodimeric SOD1.Type: ApplicationFiled: June 10, 2014Publication date: November 27, 2014Inventors: Neil R. Cashman, Avijit Chakrabartty, Rishi Rakhit, Joachim Bernhard Ostermann
-
Publication number: 20140348823Abstract: The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a histone deacetylase (HDAC) inhibitor as described herein, for example, PXD-101. In another respect, the present invention relates to a method of treating cancer (e.g., solid tumour cancer, e.g., rectal cancer, colon cancer, ovarian cancer, hematological cancer, e.g.Type: ApplicationFiled: August 7, 2014Publication date: November 27, 2014Inventors: Henri Lichenstein, Nicholas Edwards, James Ritchie, Kamille Dumong Petersen, Jane Plumb
-
Publication number: 20140348824Abstract: Methods and compositions are disclosed for predicting and treating the clinical benefit to a human renal cell carcinoma patient prior to their treatment with a VEGFR inhibitor and an Ang2 inhibitor.Type: ApplicationFiled: June 28, 2012Publication date: November 27, 2014Applicant: AMGEN INC.Inventors: Abraham Antonio Anderson, David M. Weinreich
-
Publication number: 20140348825Abstract: The present invention provides methods and compositions for the remote control of cell function based on the use of radiofrequency waves to excite nanoparticles targeted to specific cell types. The nanoparticles may be applied to the target cell extracellularly and/or expressed intracellularly. The cell type of interest expresses a temperature sensitive channel wherein excitation of the nanoparticles results in a localized temperature increase that is transduced into a cellular response. Such cellular responses may include, for example, increases in gene expression resulting in production of one or more physiologically active proteins. The expression of such proteins can be used to treat a variety of different inherited or acquired diseases or disorders in a subject. Accordingly, the invention provides a generic approach for treatment of any disease associated with a protein deficiency.Type: ApplicationFiled: August 24, 2012Publication date: November 27, 2014Applicant: THE ROCKEFELLER UNIVERSITYInventors: Jeffrey Friedman, Sarah Stanley
-
Publication number: 20140348826Abstract: The invention relates generally to a new trimerization domain useful for developing multifunctional and multivalent complexes. Particularly, the invention relates to the design of trimeric polypeptide complexes using polypeptide structural elements derived from the collagen XV protein, and their use in diagnostic and therapeutic systems in vivo and in vitro. The invention also relates to nucleic acids and vectors useful for producing said trimeric complexes.Type: ApplicationFiled: August 22, 2011Publication date: November 27, 2014Applicant: LEADARTIS, S.L.Inventors: Luis Álvarez Vallina, Ángel Cuesta-Martínez, Noelia Sainz Pastor, Laura Sanz Alcober
-
Publication number: 20140348827Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.Type: ApplicationFiled: December 19, 2012Publication date: November 27, 2014Inventors: Jeonghoon Sun, Lei-Ting Tony Tam, Huiquan Han, Keith Soo-Nyung Kwak, Xiaolan Zhou